Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Assets (2016 - 2026)

Intellia Therapeutics has reported Non-Current Assets over the past 12 years, most recently at $292.3 million for Q1 2026.

  • Quarterly Non-Current Assets fell 32.76% to $292.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Mar 2026, down 28.13% year-over-year, with the annual reading at $314.4 million for FY2025, 42.95% down from the prior year.
  • Non-Current Assets was $292.3 million for Q1 2026 at Intellia Therapeutics, down from $314.4 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $551.2 million in Q4 2024 and troughed at $215.0 million in Q2 2022.
  • The 5-year median for Non-Current Assets is $349.9 million (2023), against an average of $363.1 million.
  • The largest YoY upside for Non-Current Assets was 182.73% in 2022 against a maximum downside of 56.65% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $303.3 million in 2022, then decreased by 0.22% to $302.6 million in 2023, then skyrocketed by 82.11% to $551.2 million in 2024, then tumbled by 42.95% to $314.4 million in 2025, then dropped by 7.02% to $292.3 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Non-Current Assets are $292.3 million (Q1 2026), $314.4 million (Q4 2025), and $343.3 million (Q3 2025).